04:26 EDT 26th August 2019 | BioPortfolio

Abilify (Aripiprazole) is an atypical antipsychotic produced by <!--LGfEGNT2Lhm-->Bristol-Myers Squibb Company, with annual sales of $3m, ranking it 6th in the world for annual sales. 

Abilify is prescribed in addition to other anti-depressants for the treatment of <!--LGfEGNT2Lhm-->depression, and additionally for <!--LGfEGNT2Lhm-->bipolar disorder and schizophrenia. The FDA has recently licensed it for use in treating irritability associated with Autistic Disorder in pediatric patients (ages 6 to 17), as part of a total treatment plan.

Source; Adapted from and

Add the Abilify News Channel to your RSS reader;

Follow the Abilify Twitter feed;

Quick Search

review and buy Abilify market research data and corporate reports here